RegCell, a Japan-based company that deals with epigenetic reprogramming of disease-causing effector T-cells to create antigen-specific regulatory T-cells, announced on Wednesday that it has named Steven B Kanner, PhD as its new director.

Dr Kanner has over three decades of experience and with a focus on immunology. Presently, he serves as the chief scientific officer at Caribou Biosciences, Inc. He has earlier served as vice president and head of Biology at Arrowhead Pharmaceuticals, in various positions of increasing responsibility in both oncology and inflammation drug discovery at Astex Pharmaceuticals, Agensys/Astellas, and Bristol-Myers Squibb. Dr Kanner currently serves on the board of directors at Specific Biologics.

Professor Shimon Sakaguchi, RegCell co-founder, said, 'We are honoured to have Steve Kanner join our board of directors. Dr Kanner's profound understanding of immunology comes at a pivotal juncture for RegCell as we advance our clinical development and expand our Precision Epigenetic Reprogramming Platform. His expertise will undoubtedly be instrumental in helping us make significant progress in our mission.'